Skip to main content
Clinical Trials/NCT06208436
NCT06208436RecruitingNot Applicable

The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer Stratified by Pathologic Risk Factors

Tianjin Medical University Cancer Institute and Hospital1 site in 1 country250 target enrollmentStarted: October 7, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
250
Locations
1
Primary Endpoint
Recurrence-free survival

Study Overview

Brief Summary

This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with Stage I pancreatic cancer stratified by pathologic risk factors.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients who underwent surgical resection and were pathologically diagnosed as PDAC between 2010 and

Exclusion Criteria

  • Patients with pN1-N2, patients with pT3-T4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with R1 resection, and patients who died due to perioperative mortality within 30 days.

Outcomes

Primary Outcomes

Recurrence-free survival

Time Frame: January 2010 to February 2023

The period between surgical resection to the date of recurrence.

Secondary Outcomes

  • Overall survival(January 2010 to February 2023)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jihui Hao

Professor

Tianjin Medical University Cancer Institute and Hospital

Study Sites (1)

Loading locations...

Similar Trials